Buy Sermorelin Peptide: 29 Residues at 3357.9 g/mol

Everything in this table is published and fixed, which makes identity the cheapest thing on a listing to verify and the thing buyers check least.

One sanity check falls straight out of the first three rows. 3357.9 g/mol divided by 29 residues is 115.8 g/mol per residue, which is where a peptide of this length should land. A figure well outside that range would mean the sequence and the mass on a certificate are describing different molecules, which is the kind of internal contradiction worth two minutes of arithmetic to catch.

Milligrams are what you pay for and moles are what a receptor sees, so converting between them is the check that makes identity concrete.

The working is one division: 10 mg ÷ 3357.9 mg per millimole is 0.002978 millimoles, or 2.978 micromoles. In molecule counts that is roughly 1.79 × 10¹⁸ molecules in a labelled vial, which is a number with no practical use and one rhetorical one. It is a reminder that a milligram figure on a label is a mass, and mass only becomes a comparison once you know the molecular weight it belongs to.

That is why per-milligram comparisons across different compounds are misleading. A milligram of a 3357.9 g/mol peptide is a different count of molecules from a milligram of anything heavier or lighter, so two vials at the same dollars per milligram are not the same purchase unless the molecular weights match. Our price page keeps every rate inside one compound for exactly that reason.

The most common buyer question about this compound is whether it is the same thing as HGH, and the answer is no in a way that matters mechanically rather than semantically.

Sermorelin is the active N-terminal fragment of human growth hormone-releasing hormone. It binds the GHRH receptor on the anterior pituitary and prompts the pituitary to release the body's own growth hormone. Recombinant growth hormone is the hormone itself, supplied from outside. One asks a gland to act, the other replaces its output, and they are not interchangeable in any sense that a purchase should treat as equivalent.

That distinction is also why the marketing around this category is so slippery. Compounds that raise growth hormone by different mechanisms get grouped under one heading, sold from one storefront and compared on one price per milligram, when they differ in receptor, in regulatory status and in what has ever been approved. The next section separates the four that are most often conflated.

These four appear together on storefronts and in search results, and they differ on every axis that decides what you are buying.

Read the last column carefully, because it is the strongest single differentiator on this page. FDA's list of bulk substances that may present significant safety risks names ibutamoren mesylate under both compounding pathways and ipamorelin acetate under one, along with GHRP-2, GHRP-6 and kisspeptin-10. Sermorelin appears in none of those sections, in any category, active or withdrawn.

The four are therefore not four flavours of the same thing. They are four different regulatory objects that happen to be sold on the same page, and buying by price per milligram across them is buying on the one axis where they are most comparable and least different.

Identity is confirmed by a document tied to a lot, and there are four fields to read.

• The sequence, against the expected fragment. On lot 38-01260229 the printed sequence resolves to 29 residues with a C-terminal amide, which is the canonical GHRH(1-29) rather than a truncation or a near neighbour.
• The mass, against 3357.9 g/mol. The formula C149H246N44O42S and that weight are published under PubChem CID 16132413, and both match the vendor's own product description.
• The method. HPLC-UV-MS with 4 detected peaks. A mass spectrometric method is what makes an identity claim meaningful rather than an assertion, and the peak count tells you the run resolved more than one component.
• The lot code and date. 38-01260229, analysed 2026-02-07 and signed 2026-02-13 at MZ Biolabs in Tucson, Arizona. A certificate whose lot code is not on your vial documents somebody else's material.

What those fields do not cover is equally specific. This lot's certificate reports purity of 99.79 % and a quantity of 11.31 mg, and carries no endotoxin test and no sterility test. Identity confirmed is not sterility confirmed, and the two are separate questions on separate instruments. Our weighted source ranking puts testing scope above identity for that reason.

Buying the peptide means buying something with an unusual paper trail for this category, and the trail is worth knowing because it changes what the alternatives are.

Two FDA applications carried it under the brand name Geref, held by EMD Serono: a diagnostic presentation at 0.05 mg per ampoule under NDA 019863, with submissions going back to 1991, and a therapeutic presentation at 0.5 mg and 1 mg per vial under NDA 020443, approved in September 1997. Both now read as discontinued, on a record that states in the same breath that the discontinuation was not taken for safety or effectiveness reasons. No current US label exists. Section 503A permits a compounding pharmacy to work from a bulk substance that was a component of an approved drug product, so a prescription route exists.

The counterweight belongs in the same paragraph. The approved indications were paediatric growth hormone deficiency and pituitary diagnostics. PubMed returns 332 records mentioning the compound, 3 with it in the title and 29 tagged as clinical trials, and zero when the search adds anti-aging. ClinicalTrials.gov registers no studies naming it, so no trial identifier for this compound exists to cite. Buying a well-characterised molecule and buying a well-evidenced use are different transactions, and only the first one is settled by a certificate.